Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite-Reference-Cited by-同舟云学术

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

Published:2009-10-07 Issue:1 Volume:38 Page:92-99
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Kazui Miho,Nishiya Yumi,Ishizuka Tomoko,Hagihara Katsunobu,Farid Nagy A.,Okazaki Osamu,Ikeda Toshihiko,Kurihara Atsushi

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference25 articles.

1. Formation of the isomers of the active metabolite of prasugrel by allelic variants of the human cytochrome P450 isozymes [abstract].;Baker;Drug Metab Rev,2008

2. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

3. The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin

4. Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

5. Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

Cited by 701 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights on dual antiplatelet therapy duration following stenting for angiography-detected moderate-to-severe calcified coronary lesions;Pharmacological Research;2024-10

2. Genetic and Clinical Determinants of MACE and Haemorrhage in Antiplatelet Therapy: Insights from Pharmacogenomic Analysis;2024-09-12

3. Association of genetic variations of 3′-UTR in clopidogrel pharmacokinetic-relevant genes with clopidogrel response in Han Chinese patients with coronary artery disease;European Journal of Pharmaceutical Sciences;2024-09

4. Outcomes of Ticagrelor Versus High-dose Clopidogrel in CYP2C19 Intermediate Metabolizer Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes;Journal of Cardiovascular Pharmacology;2024-09

5. Implementing a pharmacogenomic-driven algorithm to guide antiplatelet therapy among Caribbean Hispanics: a non-randomised clinical trial;BMJ Open;2024-09